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Mass spectrometryGlycogenin-1 initiates the glycogen synthesis in skeletal muscle by the autocatalytic formation of a short ol-
igosaccharide at tyrosine 195. Glycogenin-1 catalyzes both the glucose-O-tyrosine linkage and the α1,4 glu-
cosidic bonds linking the glucose molecules in the oligosaccharide. We recently described a patient with
glycogen depletion in skeletal muscle as a result of a non-functional glycogenin-1. The patient carried a
Thr83Met substitution in glycogenin-1. In this study we have investigated the importance of threonine 83
for the catalytic activity of glycogenin-1. Non-glucosylated glycogenin-1 constructs, with various amino
acid substitutions in position 83 and 195, were expressed in a cell-free expression system and autoglucosy-
lated in vitro. The autoglucosylation was analyzed by gel-shift on western blot, incorporation of radiolabeled
UDP-14C-glucose and nano-liquid chromatography with tandem mass spectrometry (LC/MS/MS). We dem-
onstrate that glycogenin-1 with the Thr83Met substitution is unable to form the glucose-O-tyrosine linkage
at tyrosine 195 unless co-expressed with the catalytically active Tyr195Phe glycogenin-1. Our results explain
the glycogen depletion in the patient expressing only Thr83Met glycogenin-1 and why heterozygous carriers
without clinical symptoms show a small proportion of unglucosylated glycogenin-1.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Glycogen is composed of highly branched glucose polymers and
serves as an important energy supply within cells. The main glycogen
depots are found in the liver and in the skeletal muscle. Liver glyco-
gen releases glucose to the blood stream to maintain blood glucose
levels and skeletal muscle glycogen serves as rapidly accessible ener-
gy during muscle contraction. The high energy consumption in skele-
tal muscle makes it susceptible to metabolic disorders, which
constitute a heterogenous group of diseases with impaired energy
production due to enzymatic deﬁciencies in the metabolism of fatty
acids or glycogen. A subgroup of the metabolic disorders are the gly-
cogenoses characterized by accumulation or depletion of glycogen
due to defects in the glycogen degradation or synthesis pathways
[1]. Glycogen synthesis is initiated by the autoglucosylation of the
protein glycogenin [2,3]. Two different genes code for the two iso-
forms of glycogenin: glycogenin-1 is a 38 kDa protein expressed in
muscle and heart [4–6] and glycogenin-2 is a 66 kDa protein and
the predominant isoform in liver [7–9].
Glycogenin-1 is a glycosyltransferase (EC 2.4.1.186) catalyzing
two autoglucosylation reactions using UDP-glucose as donor46 313422886.
rights reserved.substrate (Fig. 1A). First, a glucose-O-tyrosine linkage is formed
with the hydroxyl group of tyrosine 195 [10–14] and second, several
α1,4 glucosidic linkages are formed to produce an oligosaccharide
containing approximately 8–13 glucose residues [13,15,16]. The
priming oligosaccharide chain is required for elongation by glycogen
synthase (EC 2.4.1.11) and the introduction of α1,6 branching points
by branching enzyme (EC 2.4.1.18) to produce glycogen [17]. Each
glycogen granule in muscle cells contains approximately 30,000 glu-
cose residues with numerous non-reducing ends for rapid access to
glucose [18].
We recently described the ﬁrst patient with a disease associated
with glycogenin-1 mutations [19]. The patient was admitted with
sudden cardiac arrest at age 27 and skeletal muscle revealed pro-
found glycogen depletion (Fig. 1B). Sequencing of the glycogenin-1
gene, GYG1, showed a nonsense mutation in one allele and a missense
mutation, Thr83Met, in the other. Only the allele with the missense
mutation was expressed and resulted in inactivation of the autoglu-
cosylation of glycogenin-1 necessary for the priming of glycogen syn-
thesis in muscle. In normal controls virtually all glycogenin-1
molecules were autoglucosylated whereas a heterozygous carrier of
the Thr83Met mutation demonstrated a small proportion of ungluco-
sylated glycogenin-1 in skeletal muscle [19].
In this study we have investigated the importance of the Thr83 in
human glycogenin-1 for autoglucosylation and the formation of a
glucose-O-tyrosine linkage at tyrosine 195. We demonstrate that
Fig. 1. A: Schematic illustration of glycogen synthesis. Glycogenin-1 initially autoglucosylates at tyrosine 195 and the oligosaccharide is then elongated by glycogen synthase and
branching enzyme into a glycogen granule. The electron micrograph shows glycogen granules (arrow) within skeletal muscle. B: Cross sections of skeletal muscle from the patient
with the glycogenin-1 Thr83Met mutation and a control stained with Periodic Acid Schiff (PAS) reagent to detect glycogen. The muscle ﬁbers of the patient demonstrate glycogen
depletion.
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form the glucose-O-tyrosine linkage at tyrosine 195. However,
glycogenin-1 with the Thr83Met mutation is glucosylated by a cata-
lytically active glycogenin-1 protein.
2. Material and methods
2.1. Vector construction
The coding region of GYG1 was ampliﬁed from cDNA prepared
from patient or control skeletal muscle using the primers 5′-ATG
ACA AGA TCA GGC CTT T-3′ and 5′-CTA CTG GAG GTA AGT GTC-3′
and inserted downstream of the 6xHis tag in the pEXP5-NT/TOPO
vector (Invitrogen, Carlsbad, CA). The cloned sequence was identical
to GenBank accession number NM_001184720 with the exception
of c.248C>T causing the amino acid change Thr83Met in the patient
cDNA [19]. The wild type vector prepared from the control muscle
was used as a template to make additional constructs with amino
acid alteration at position 83 or 195 of glycogenin-1. The amino acid
substitutions were induced by using QuikChange®II Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA) according to manufacturer's
protocol and the primers listed in Supplementary Table 1. All con-
structs were conﬁrmed by sequencing.
2.2. Cell-free expression and in vitro glucosylation
Recombinant glycogenin-1 was expressed from the pEXP5-NT/
TOPO vectors (above) using EasyExpress Protein Synthesis Kit (Qia-
gen, Hilden, Germany) according to the manufacturer's protocol.
Glycogenin-1 was allowed to autoglucosylate in 50 mM Hepes pH
7.5, 5 mM MnCl2, 0.5 mM DTT in the presence of 0.1 M UDP-glucose(Calbiochem) or 0.01 μM UDP-14C-glucose (PerkinElmer) in 30 °C
for 1 h [20]. The recombinant glycogenin-1 was denatured using
Laemmli sample buffer with 5% β-mercaptoethanol and run on a
10% Bis–Tris gel (Invitrogen) for 1 h with 200 V followed by electro-
blotting to Invitrolon™ PVDF ﬁlters at 20 V for 10 min. The incorpora-
tion of UDP-14C-glucose was detected on X-ray ﬁlm and glycogenin-1
was detected with Anti-human glycogenin antibody clone M07
(Abnova, Taipei City, Taiwan) 1:500 and Western Breeze™
(Invitrogen).
2.3. Puriﬁcation, gel ﬁltration and alpha-amylase treatment of
glycogenin-1
Autoglucosylated glycogenin-1 was puriﬁed with the 6xHis tag
using Ni-NTA Magnetic Agarose beads (Qiagen) according to the
manufacturer's instruction.
Glycogenin-1 eluates from Ni-NTA afﬁnity puriﬁcation were run
on a Superdex 200 5/150 analytical gel ﬁltration column connected
to an ÄKTA puriﬁer (GE Healthcare). The buffer was 25 mM sodium
phosphate pH 7.4, 150 mM sodium chloride, 0.05% Tween 20. Flow
rate was 0.15 ml/min and 100 μl fractions were collected.
Glycogenin-1 chromatograms were compared with a column stan-
dard curve of ferritin (440 kDa), aldolase (158 kDa), ovalbumin
(43 kDa) and RNase A (13.7 kDa). Peak fractions were analyzed
with Western blot using the Anti-human glycogenin antibody clone
M07.
The glycogenin-1 was treated with 10 μg/ml human alpha-
amylase (Sigma-Aldrich, Schnelldorf, Germany) in a total volume of
200 μl PBS pH 6.5 for 1 h at 37 °C while still attached to the beads.
The alpha-amylase was then removed by rinsing. Glycogenin-1 was
released from the beads by boiling in Laemmli sample buffer prior
Fig. 2. Wild type and Thr83Met glycogenin-1 proteins expressed in a cell-free expres-
sion system, autoglucosylated in vitro in the presence of UDP-glucose and visualized
with western blot (A) and autoradiography after incorporation of UDP-14C-glucose
(B). Wild type glycogenin-1 incorporated glucose in the presence of UDP-glucose (A
and B, lane 1) that was cleaved with alpha-amylase (A and B, lane 3). Thr83Met
glycogenin-1 did not incorporate glucose (A and B, lane 4) and was not affected by
alpha-amylase (A and B, lane 6) indicating that Thr83Met glycogenin-1 was not cata-
lyzing the glucose-O-tyrosine 195 linkage.
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glycogenin-1 was excised for in-gel trypsinization.
2.4. In-gel tryptic digestion and mass spectrometry
In-gel trypsinization was performed as described by Shevchenko
[21]. The excised gel fragments were destained in 12.5 mM
NH4HCO3 with 50% acetonitrile and in 25 mM NH4HCO3 with 50%
methanol. The samples were incubated in 10 mM DTT in 56 °C for
1 h and in 55 mM iodoacetamide for 45 min at room temperature.
The gel pieces were rinsed as described above, dried in a vacuum cen-
trifuge and incubated with digestion buffer (50 mM NH4HCO3, 0.1%
acetonitrile, 10 ng/μl trypsin, proteomics grade, Sigma-Aldrich) at
37 °C overnight. Peptides were extracted in 50% acetonitrile/1% tri-
ﬂuoracetic acid and the supernatant was evaporated to dryness in a
vacuum centrifuge. Prior to MS analysis, the peptides were reconsti-
tuted in 0.2% formic acid.
2.5. Nano-LC/MS/MS analysis
The samples were injected using a HTC-PAL autosampler (CTC An-
alytics AG, Zwingen, Switzerland) connected to an Agilent 1100 bina-
ry pump (Agilent Technologies, Palo Alto, CA). The peptides were
trapped on a precolumn (45×0.075 mm i.d.) and separated on re-
versed phase column, 200×0.050 mm. Both columns were packed
in-house with Reprosil-Pur 3 mm C18-AQ particles. The ﬂow through
the analytical column was reduced by a split to approximately 100 nl/
min. A linear gradient of 10–50% acetonitrile in 0.2% formic acid dur-
ing 40 min was used for separation of the peptides. The nanoﬂow LS/
MS/MS was performed on a hybrid linear ion trap-Fourier transform
ion cyclotron resonance (FTICR) mass spectrometer equipped with a
7 T ICR magnet (LTQ-FT, Thermo Fisher Scientiﬁc, Bremen, Germany).
The spectrometer was operated in data-dependent mode, automati-
cally switching to MS/MS mode. MS-spectra were acquired in the
FTICR, while MS/MS-spectra were acquired in the linear ion trap.
For each scan of FTICR, the ﬁve most intense, doubly or triply charged,
ions were sequentially fragmented in the linear ion trap by collision
induced dissociation (CID).
2.6. MS data analysis
For peptide identiﬁcation, all tandem mass spectra were searched
by an in-house version of MASCOT (Version 2.2.0; Matrix Science,
London). LTQ-FT .raw ﬁles were converted to .dta ﬁles by the Xcalibur
software utility extract_msn (Thermo Fisher Scientiﬁc). The search
parameters were set to: peptide tolerance, 10 ppm; MS/MS accuracy,
0.6 Da; enzyme, trypsin; one missed cleavage allowed, taxonomy;
human, database; SwissProt 101005 (20,259 sequences), ﬁxed carba-
midomethyl modiﬁcation of cysteine; variable oxidation of methio-
nine and variable substitution of tyrosine by phenylalanine. The .dta
ﬁle searches were repeated according to the parameters above, with
the exception of using semitryptic enzyme speciﬁcity to account for
non-tryptic N- or C-terminal end of the peptides.
For glycopeptide identiﬁcation, LTQ-FT .raw ﬁles were evaluated
manually and searched for precursor ions that were 1–8 hexose resi-
dues (162.0528 Da–1296.4224 Da) heavier than co-eluting (±5 min)
non-glucosylated peptides that included tyrosine 195. The MS2 spec-
tra of such precursor ions were surveyed for neutral losses corre-
sponding to hexose residues and individually converted to .mzXML
format using the readW application. mzXML ﬁle searches were per-
formed with the mMass application [22] with precursor ion masses
manually deﬁned by subtracting the monoisotopic mass of hexose
residues from the FTICR-MS1 mass measured precursor ion. Search
parameters were set to: peptide tolerance, 10 ppm; MS/MS accuracy,
0.6 Da, enzyme semitrypsin, one missed cleavage allowed, taxonomy;
human, database; Swissprot 101005 (20,259 sequences), ﬁxedcarbamidomethyl modiﬁcation of cysteine and variable oxidation of
methionine.
3. Results
3.1. Glycogenin-1 Thr83Met is incapable of autoglucosylation
To investigate the effect of the glycogenin-1 Thr83Met mutation in
vitro we expressed apo-glycogenin-1 in an E. coli based cell-free pro-
tein expression system and studied the autoglucosylation after addi-
tion of UDP-glucose. Kinetics of wild type glycogenin-1 have
demonstrated that the autoglucosylation of wild type glycogenin-1
is nearly complete within 20 min [23].
The recombinant unglucosylated glycogenin-1 was detected as a
40 kDa band including the 6xHis tag on Western blot using a mono-
clonal antibody to human glycogenin-1 (Fig. 2A, lane 2). After the ad-
dition of UDP-glucose to wild type glycogenin-1 a mobility shift of
approximately 1 kDa was observed consistent with autoglucosylation
of 8–13 glucose residues (Fig. 2A, lane 1). About half of the
glycogenin-1 molecules demonstrated this shift in molecular weight
indicating that the recombinant wild type glycogenin-1 molecules
were not optimally autoglucosylated in this system. To further con-
ﬁrm that the gel-shift was a result of autoglucosylation the samples
were treated with alpha-amylase that speciﬁcally cleaves the α1,4
glucosidic linkages between the glucose residues of the oligosaccha-
ride chain. This treatment resulted in a reduction of the molecular
weight similar to that of wild type glycogenin-1 before the addition
of UDP-glucose (Fig. 2A, lane 3).
Glycogenin-1 with the threonine to methionine substitution in
position 83 showed no size shift after 60 min in the presence of
UDP-glucose and the molecular weight was unchanged by the
alpha-amylase treatment indicating that it was not at all autoglucosy-
lated (Fig. 2A, lanes 4–6).
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pression system were analyzed with size-exclusion chromatography.
Western blot of chromatography fractions showed detectable
glycogenin-1 as dimers or tetramers in both samples. However, the
recombinant protein was also found as aggregates which might be
an explanation for the incomplete autoglucosylation of wild type
glycogenin-1 (Fig. 2A, lane 1).
To study the glucose-O-tyrosine linkage at position 195 in mutant
and wild type glycogenin-1 the experiment was repeated with UDP-
14C-glucose and analyzed by autoradiography (Fig. 2B). Wild type
glycogenin-1 showed incorporation of glucose in the presence of
UDP-glucose (Fig. 2B, lane 1) and most of it was cleaved off by
alpha-amylase treatment (Fig. 2B, lane 3). Glycogenin-1 with the
Thr83Met mutations showed no incorporation of glucose (Fig. 2B,
lanes 4–6). These results indicate that the glycogenin-1 with the
Thr83Met mutation was not capable of catalyzing the glucose-O-
tyrosine 195 linkage. To structurally characterize the glucosylation
pattern mass spectrometry was applied, using nano-LC/MS/MS.
After adding UDP-glucose, the samples were treated with alpha-
amylase in order to simplify the mass spectrometric analysis of gluco-
sylated peptides. Several semitryptic and tryptic peptides of different
length containing tyrosine 195 were detected and identiﬁed by the
MASCOT algorithm from both wild type and Thr83Met glycogenin-1
(Table 1). Most peptides derived from wild type glycogenin-1 sam-
ples were modiﬁed with hexose (glucose) in the range between two
and eight glucose molecules. For several of these glucosylated pep-
tides, MS/MS experiments also revealed the glucose moieties to be se-
lectively attached to Tyr195 (Suppl Fig. 1E–G). Interestingly, not a
single peptide containing only one glucose was detected suggesting
that alpha-amylase is unable to cleave α1,4 glucosidic linkages closer
than two glucose residues from the peptide backbone. None of the
identiﬁed peptides derived from Thr83Met glycogenin-1 that includ-
ed Tyr195 showed any glucose modiﬁcations conﬁrming that
Thr83Met glycogenin-1 was unable to form the glucose-O-tyrosine
linkage at position 195. Tyrosines at position 187 and 197 were
never found to be glucosylated.
3.2. Threonine at position 83 is not speciﬁc for catalytically active
glycogenin-1
Threonine in position 83 of glycogenin-1 is a phylogenetically con-
served amino acid within a potential UDP-binding fold [24,25]. ByTable 1
Peptides containing tyrosine 195 from wild type and Thr83Met glycogenin-1 detected by m
Hexose modiﬁed tyrosin is underlined and Δppm larger than 10 is marked in red. *MASCO
algorithm to resolve complex post-translational modiﬁcations.site-directed mutagenesis we changed threonine at position 83 to
amino acids with different side chains and chemical properties
(Fig. 3A). The different glycogenin-1 variants were expressed in the
cell-free expression system. We then analyzed the ability of
glycogenin-1 with these different modiﬁcations to autoglucosylate
with the gel-shift assay. In addition to wild type glycogenin-1 with
threonine at position 83, glycogenin-1 with serine at position 83
was also capable of autoglucosylation (Fig. 3B). This was not the
case for glycogenin-1 with methionine, alanine, cysteine, phenylala-
nine, tyrosine or valine substitutions at position 83 (Fig. 3B). Autoglu-
cosylation experiments with UDP-14C-glucose demonstrated glucose
incorporation of glycogenin-1 with either threonine or serine in posi-
tion 83 but not with the other amino acids tested (Fig. 3C). These re-
sults demonstrate that threonine in position 83 was not
indispensable for catalytic function of glycogenin-1. A change of thre-
onine to serine, which is similar to threonine with respect to size and
presence of a hydroxyl group, will thus retain the catalytic properties
of the protein. Glycogenin-1 constructs with the bulkier tyrosine,
which also contains a hydroxyl group, as well as alanine, cysteine
and valine that have a similar size as threonine but lack a hydroxyl
group, showed no autoglucosylation.
3.3. Thr83Met glycogenin-1 is glucosylated by a catalytically active
glycogenin-1
Gel ﬁltration analysis has shown that 95% of the glycogenin-1 mol-
ecules exist as dimers [20] and it has been demonstrated that the cat-
alytically inactive Lys85Gln rabbit glycogenin-1 could be glucosylated
by a catalytically active glycogenin-1 within a heterodimer [26]. Re-
placement of the glucose-binding tyrosine 195 with phenylalanine
(Tyr195Phe) produces a glycogenin-1 that is catalytically active but
incapable of binding glucose [27,28].
To study whether the catalytically inactive human glycogenin-1
with the Thr83Met mutation could be glucosylated we co-expressed
recombinant Thr83Met and Tyr195Phe glycogenin-1 and studied
autoglucosylation after the addition of UDP-14C-glucose (Fig. 4A).
No incorporation of glucose in the Tyr195Phe glycogenin-1 sam-
ple was detected (Fig. 4A, lane 3) but when Thr83Met and Tyr195Phe
glycogenin-1 were co-expressed the Thr83Met glycogenin-1 was glu-
cosylated (Fig. 4A, lane 2) indicating a glucosylation at Tyr195 of
glycogenin-1 with the Thr83Met mutation, catalyzed by glycogenin-
1 with the Tyr195Phe mutation.ass spectrometry.
T ion scores are not available for all glucosylated peptides due to the inability of the
Fig. 3. Threonine 83 of human glycogenin-1 was replaced using site-directed mutagenesis by amino acids with different side-chains (A). Mutated glycogenin-1 proteins were autoglu-
cosylated in vitro. 2 μg of protein were separated on a SDS-PAGE and the autoglucosylation was assayed with gel-shift on western blot (B) and for incorporation of UDP-14C-glucose
with autoradiography (C). Only threonine and serine in position 83 produced a catalytically active glycogenin-1 that incorporated glucose (B and C, lanes 1 and 3).
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variants in the co-expression experiment and showed that at least
two hexoses had been added to tyrosine 195 of Thr83Met
glycogenin-1 (Fig. 4B, Table 2).
4. Discussion
We recently described the ﬁrst disease associated with a severe
defect in glycogenin-1, a protein necessary for priming of glycogen
synthesis in muscle. The investigations demonstrated profound gly-
cogen depletion in muscle and mutations in the gene coding for
glycogenin-1, GYG1. The patient was compound heterozygous for a
nontranslated nonsense mutation in one allele and a missenseFig. 4. A: The catalytically active Tyr195Phe glycogenin-1 and Thr83Met glycogenin-1 protein
glucose was detected with autoradiography. Tyr195Phe glycogenin-1 was unable to bind glu
B: MS2 spectrum showing the fragmentation pattern of the glycopeptide IYNLSSISIY195SYLP
with nano-LC/MS/MS. The peptide had two hexoses (glucoses) attached to tyrosine 195.mutation, Thr83Met, in the other. A heterozygous carrier of only the
Thr83Met mutation had no clinical signs or symptoms but a small
proportion, less than 50%, of unglucosylated glycogenin-1 in muscle
and cultured myoblasts [19]. These ﬁndings raised questions related
to autoglucosylation of human glycogenin-1 and the importance
and function of threonine at position 83. Autoglucosylation of
glycogenin-1 has previously been studied in rabbit skeletal muscle
glycogenin-1, which is highly homologous to human glycogenin-1
[5]. The autoglucosylation reaction includes binding and hydrolysing
UDP-glucose, the formation of a glucose-O-tyrosine linkage at posi-
tion 195 and the elongation of the oligosaccharide with several α1,4
glucosidic linkages. In this study we investigated autoglucosylation
of the human glycogenin-1 and the effect of the Thr83Mets were co-expressed and allowed to autoglucosylate in vitro. Incorporation of UDP-14C-
cose (lane 3) but glucosylated the Thr83Met glycogenin-1 when co-expressed (lane 2).
AFK from Thr83Met glycogenin-1 co-expressed with Tyr195Phe glycogenin-1 detected
Table 2
MS detection of peptides containing tyrosine 195 or the mutated phenylalanine 195 from a co-expression of Thr83Met and Tyr195Phe glycogenin-1.
Non-native phenylalanine is marked in red and hexose modiﬁed tyrosin is underlined.
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cell-type containing UDP-glucose we expressed glycogenin-1 in a
cell-free system free from UDP-glucose and studied the autoglucosy-
lation after addition of UDP-glucose in vitro.
By means of autoradiography, gel-shift assay and mass spectrom-
etry we demonstrated that glycogenin-1 carrying the Thr83Met sub-
stitution is unable to catalyze the ﬁrst steps in the autoglucosylation
reaction to form the glucose-O-tyrosine linkages at position 195.
Threonine 83 is located within the conserved domain II of
glycogenin-1 [25] and mutagenesis of the lysine at position 85 has
shown that it is necessary for the catalytic function of rabbit glyco-
genin [26]. Crystallization of rabbit glycogenin has demonstrated a
β-α-β Rossman-like fold, common to the nucleotide binding domains
of other glycosyltransferases, in the N-terminal part of the protein in
close vicinity to threonine 83 [24], suggesting that threonine 83 may
also be important for the binding or hydrolyzing of UDP-glucose.
To investigate how speciﬁc threonine at position 83 is for the
autoglucosylation of human glycogenin-1 we applied site-directed
mutagenesis to study the effects of various amino acid substitutions
at this position. Threonine 83 was exchanged to amino acids of differ-
ent size and with different side chains. Our results indicate that the
hydroxyl group on threonine is important for the function. Serine is
like threonine a small amino acid with a hydroxyl group and a change
of threonine 83 to serine 83 did not inhibit autoglucosylation. Alanine
and valine are both small amino acids and essentially isosteric with
threonine but in contrast to serine and threonine they have no hy-
droxyl groups. Changing threonine 83 to alanine 83 or valine 83 abol-
ished autoglucosylation. The presence of a hydroxyl group indicates
that the side chain of Thr83 may be involved in a hydrogen bond.
However, the crystal structure of rabbit glycogenin (PDB 1LL2 [24])
shows that the geometry is incorrect for a proper hydrogen bond to
form despite being in close proximity (b3 Å) to the backbone amide
proton of the conserved, catalytically important Asp163. It is still pos-
sible that a stabilizing hydrogen bond is important transiently during
the catalytic cycle.
Thr83 is contiguous in sequence to Val82 which forms one side of
the uridine binding pocket [24]. Smaller or larger amino acid in posi-
tion 83 could switch the helix in which these residues reside enough
to adversely affect UDP-glucose binding.
Gel-ﬁltration analysis has demonstrated that glycogenin predom-
inantly exists as dimers [20]. Several possible models for the autoglu-
cosylation of glycogenin have been proposed. The glucosylation can
be either within dimers, interdimeric or between monomers of
glycogenin-1 [26,29]. It has been suggested that the ﬁrst two or
three glucose residues of the priming oligosaccharide have to be
added within a dimer since the bound UDP-glucose and tyrosine
195 are too far separated (10 Å) in a single glycogenin molecule to
allow for autoglucosylation [24]. We demonstrated that human
glycogenin-1 with the Thr83Met substitution was glucosylatedwhen co-expressed with Tyr195Phe glycogenin-1 that is catalytically
active but cannot be autoglucosylated itself since the essential hy-
droxyl of the aromatic residue is missing at position 195 [12]. By
nano-LC/MS/MS we demonstrated two glucose residues attached to
Tyr195 of the Thr83Met glycogenin-1 when it was co-expressed
with Tyr195Phe glycogenin-1. One possible model is that the
tyrosine-O-linkage as well as at least one α1,4 glucosidic linkage at-
tached to Thr83Met glycogenin-1 were catalyzed by the Tyr195Phe
within a heterodimer.
That intra-dimeric glucosylation can take place also in vivowas ev-
ident from the ﬁndings in a healthy heterozygous carrier of the
Thr83Met mutation [19]. In this case a small proportion of the
glycogenin-1 was unglucosylated compatible with the presence of
approximately 25% nonglucosylated Thr83Met glycogenin-1in homo-
dimers and the others being either Thr83 glycogenin-1 homodimers
or Thr83Met/Thr83 heterodimers. This explains why the heterozy-
gous carriers so far identiﬁed have no signs or symptoms related to
defective skeletal muscle energy metabolism.
In conclusion we demonstrate that glycogenin-1 with the disease
causing amino acid substitution Thr83Met is unable to catalyze the
glucose-O-tyrosine 195 linkage, the ﬁrst step in the autoglucosylation
of glycogenin-1. However, Thr83Met glycogenin-1 is glucosylated by
the enzymatically active Tyr195Phe glycogenin-1 molecule.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2011.11.017.
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